Department of Laboratory Medicine, Wilhelminenspital, Vienna, Austria.
Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):65-8. doi: 10.1016/j.ejogrb.2009.06.010. Epub 2009 Jul 19.
A number of serum tumor markers have been investigated to aid clinicians in the differential diagnosis of ovarian masses. Serum C-reactive protein (CRP) is a widely used biomarker of inflammation and has been previously shown to be a promising biomarker in patients with ovarian cancer.
In a retrospective single-center study, we evaluated serum CRP in 576 patients with benign and in 242 patients with malignant (ovarian tumors of low malignant potential [LMP]: n=44, epithelial ovarian cancer [EOC]: n=198) ovarian masses. Results were correlated to clinical data.
Median (25th, 75th percentiles) serum CRP in patients with benign ovarian tumors, with ovarian tumors of LMP, and with EOC were 0.5 (0.5, 0.6)mg/dL, 0.5 (0.5, 0.9)mg/dL, and 1.36 (0.5, 4.9)mg/dL, respectively (p<0.001). In the subgroup of patients with EOC, serum CRP significantly correlated with FIGO stage (p<0.001), residual tumor mass (p<0.001), and patients' age (p=0.04), but not with tumor grade (p=0.2) and histologic type (p=0.4). In univariable and multivariable models including serum CRP, serum CA 125, and patients' age, serum CRP independently predicted the presence of malignant ovarian masses (p<0.0001; Odds Ratio [OR] 5.3, 95% Confidence Interval [CI] 3.8-7.4). Serum CRP had a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying malignant ovarian masses of 49.8%, 84.1%, 57.1%, and 79.8%, respectively.
Serum CRP is associated with the presence of malignant ovarian tumors independent of serum CA 125 and patients' age and can therefore be used as additional diagnostic marker in the differential diagnosis of ovarian masses.
许多血清肿瘤标志物已被研究用于帮助临床医生鉴别卵巢肿块。血清 C 反应蛋白（CRP）是一种广泛应用的炎症生物标志物，先前已被证明在卵巢癌患者中是一种很有前途的生物标志物。
在一项回顾性单中心研究中，我们评估了 576 例良性卵巢肿块患者和 242 例恶性卵巢肿块（低恶性潜能肿瘤[LMP]：n=44，上皮性卵巢癌[EOC]：n=198）患者的血清 CRP。结果与临床数据相关联。
良性卵巢肿瘤、LMP 卵巢肿瘤和 EOC 患者的血清 CRP 中位数（25 分位数，75 分位数）分别为 0.5（0.5，0.6）mg/dL、0.5（0.5，0.9）mg/dL 和 1.36（0.5，4.9）mg/dL（p<0.001）。在 EOC 患者亚组中，血清 CRP 与 FIGO 分期（p<0.001）、残余肿瘤量（p<0.001）和患者年龄（p=0.04）显著相关，但与肿瘤分级（p=0.2）和组织学类型（p=0.4）无关。在包括血清 CRP、血清 CA 125 和患者年龄的单变量和多变量模型中，血清 CRP 独立预测恶性卵巢肿块的存在（p<0.0001；优势比[OR] 5.3，95%置信区间[CI] 3.8-7.4）。血清 CRP 对识别恶性卵巢肿块的敏感性、特异性、阳性预测值（PPV）和阴性预测值（NPV）分别为 49.8%、84.1%、57.1%和 79.8%。
血清 CRP 与恶性卵巢肿瘤的存在相关，独立于血清 CA 125 和患者年龄，因此可作为卵巢肿块鉴别诊断的附加诊断标志物。
